Want to see AU:BDX full AI Analyst Report?
BCAL Diagnostics Limited (BDX) AI Stock Analysis
BCAL Diagnostics Limited
(ASX:BDX)
The overall score of 43 is severely weighed down by BCAL Diagnostics' precarious financial health, marked by expanding net losses, a negative equity position, and persistent cash burn. Poor valuation metrics driven by unprofitability further suppress the score. While technical indicators show some short-to-medium-term upward momentum, the overarching structural challenges and long-term bearish trend dominate the evaluation.
BCAL Diagnostics Limited (BDX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 30.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 153.28K
- Price to Earnings (P/E)
- -4.2
- Beta (1Y)
- 0.51
- Revenue Growth
- 743.51%
- EPS Growth
- -1.52%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
BCAL Diagnostics Limited Business Overview & Revenue Model
Company Description
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for pot...
How the Company Makes Money
Revenue-generating mechanisms for BCAL Diagnostics Limited (BDX) are not publicly available in sufficient detail to describe a factual revenue model, key revenue streams, or significant partnerships without speculation; therefore: null
BCAL Diagnostics Limited Financial Statement Overview
Summary
BCAL Diagnostics is experiencing severe financial distress, warranting the lowest possible score. The company reported mounting net losses of $7.37M, negative equity of -$826.2K, and total debt surging to $6.92M. Structural cash burn persists with a negative free cash flow of $6.62M, presenting substantial solvency risks.
Income Statement
12Very NegativeBalance Sheet
10Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 182.51K | 182.51K | 21.64K | 3.10M | 2.79M | 718.67K |
| Gross Profit | -534.72K | -534.72K | 21.64K | 3.10M | 2.79M | 698.06K |
| EBITDA | -8.67M | -8.67M | -6.19M | -5.45M | -7.72M | -4.06M |
| Net Income | -7.37M | -7.37M | -7.24M | -6.40M | -5.06M | -3.39M |
Balance Sheet | ||||||
| Total Assets | 7.66M | 7.66M | 9.91M | 12.27M | 8.37M | 10.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.59M | 1.59M | 4.52M | 6.47M | 3.17M | 9.57M |
| Total Debt | 6.92M | 6.92M | 2.38M | 1.52M | 1.06M | 0 |
| Total Liabilities | 8.49M | 8.49M | 3.69M | 3.68M | 3.16M | 950.42K |
| Stockholders Equity | -826.19K | -826.19K | 6.22M | 8.59M | 5.21M | 9.64M |
Cash Flow | ||||||
| Free Cash Flow | -6.62M | -6.62M | -6.92M | -5.67M | -6.41M | -7.25M |
| Operating Cash Flow | -6.16M | -6.16M | -6.14M | -4.52M | -6.05M | -3.22M |
| Investing Cash Flow | -1.44M | -1.44M | -787.67K | -1.15M | 3.64M | -4.03M |
| Financing Cash Flow | 4.66M | 4.66M | 4.97M | 8.97M | 13.24K | 9.41M |
BCAL Diagnostics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 63.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:BDX.
BCAL Diagnostics Limited Peers Comparison
Overall Rating
AU:SHL72Outperform
AU:ACL66Neutral
AU:HLS51Neutral- AU:BDX43Neutral
AU:LDX41Neutral
AU:RHY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:SHL | 72Outperform | AUD 9.67B | 15.91 | 7.20% | 5.52% | 14.40% | 15.11% |
| AU:ACL | 66Neutral | AUD 615.51M | 26.70 | 15.80% | 3.94% | -0.90% | -25.09% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:HLS | 51Neutral | AUD 359.46M | -0.86 | -114.08% | ― | 2.16% | 21.05% |
| AU:BDX | 43Neutral | AUD 30.97M | -4.18 | -881.94% | ― | 743.51% | -1.52% |
| AU:LDX | 41Neutral | AUD 59.29M | -6.49 | -35.89% | ― | 1.36% | 39.13% |
| AU:RHY | 38Underperform | AUD 22.94M | -3.56 | -205.17% | ― | 239.64% | -37.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:BDX | BCAL Diagnostics Limited | 0.08 | -0.01 | -6.67% | |
| AU:HLS | Healius Limited | 0.49 | -0.39 | -44.07% | |
| AU:RHY | Rhythm Biosciences Ltd. | 0.06 | -0.03 | -29.21% | |
| AU:LDX | Lumos Diagnostics Holdings Ltd. | 0.06 | -0.18 | -75.00% | |
| AU:SHL | Sonic Healthcare Limited | 19.57 | -0.30 | -1.52% | |
| AU:ACL | Australian Clinical Labs Ltd | 3.30 | 0.80 | 32.11% |
BCAL Diagnostics Limited Corporate Events
BCAL Diagnostics Showcases BREASTESTplus 2 Research at Global Lipidomics Conference
BCAL Diagnostics has showcased the scientific research underpinning its blood-based breast cancer test BREASTESTplus 2 at the Australian Lipid Meeting and International Lipidomic Society Conference in Perth. The poster presentation detailed the clini...
BCAL Diagnostics Evolves Into National Early Cancer Detection Platform
BCAL Diagnostics Limited is an Australian healthcare company focused on developing and commercialising blood-based technologies for earlier cancer detection across multiple indications. Its diagnostics platform includes tests for breast, pancreatic,...
BCAL Diagnostics Clinically Validates BREASTESTplus 2 Ahead of National Launch
BCAL Diagnostics has completed clinical validation of its next-generation BREASTESTplus 2 blood test for the detection of early-stage breast cancer in women aged 30 and over across all breast densities. The test, which showed sensitivity of 80.3% and...
BCAL rolls out Avantect multi-cancer blood test across Australia
BCAL Diagnostics has begun a phased rollout of the Avantect Multi-Cancer early detection blood test in Australia, initially targeting Sydney and Melbourne before a broader national expansion. The test, developed with ClearNote Health, screens for can...
BCAL Diagnostics Sets October AGM, Streamlines Digital Shareholder Participation
BCAL Diagnostics has called its Annual General Meeting for 19 October 2026 in Sydney, with shareholders able to attend both in person and online via a Zoom webinar. Online participants will be able to submit questions but must lodge their votes in ad...
BCAL Diagnostics distances itself from merger talk as it pursues scale and synergies
BCAL Diagnostics has clarified its position regarding Genetic Signatures and Microba Life Sciences following media speculation about a possible three-way merger among the medtech firms. The company reiterated that its stance toward Genetic Signatures...
BCAL Diagnostics pushes for board shake‑up at Genetic Signatures after lifting stake
BCAL Diagnostics has moved to reshape the board of fellow ASX-listed diagnostics firm Genetic Signatures after increasing its stake to 18.46%, issuing a formal request for a shareholder meeting to vote on removing director Michael Aicher and appointi...
BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows
BCAL Diagnostics reported FY26 progress highlighting commercial uptake of its BREASTEST plus test, with more than 200 tests sold since launch and growing digital infrastructure through earlydectection.com.au integrated into widely used GP practice sy...
BCAL Diagnostics Files Updated Corporate Governance Statement with ASX
BCAL Diagnostics has lodged its latest corporate governance statement for the year to 30 June 2026, confirming that the document is current as of 28 August 2026 and accessible via its website in line with ASX Listing Rule requirements. The accompanyi...
BCAL Diagnostics widens early cancer platform as losses deepen and balance sheet weakens
BCAL Diagnostics reported a 10% decline in revenue to $2.55 million for the year to 30 June 2026 and a slightly higher net loss of $7.37 million, with no dividends declared and a net deficiency in tangible assets per security. The audited financial s...
BCAL Diagnostics boosts Genetic Signatures stake to deepen diagnostics platform
BCAL Diagnostics has lifted its stake in molecular diagnostics firm Genetic Signatures to 18.46% by acquiring an additional 18.75 million shares for $1.5 million in cash at $0.08 per share. The company views Genetic Signatures’ 3base platform a...
BCAL Diagnostics Issues 1.5 Million Unquoted Convertible Notes
BCAL Diagnostics Limited has notified the market of the issue of 1,500,000 unquoted convertible notes, designated as BDXAI, with an issue date of August 25, 2026. The notes form part of previously announced transactions and are not intended to be quo...
BCAL Diagnostics Issues 1 Million Unquoted Convertible Notes
BCAL Diagnostics Limited has notified the market of the issue of 1,000,000 unquoted convertible notes, designated as BDXAI, with an issue date of 14 August 2026. The move expands the company’s pool of unquoted equity-linked securities and may p...
BCAL Diagnostics to Raise Capital via Convertible Note Placement
BCAL Diagnostics Limited has notified the ASX of its intention to issue up to 4,900,000 convertible notes under a placement or similar capital-raising structure. The securities, designated under the ASX code BDXAI, are scheduled for issue on 26 Augus...
BCAL Diagnostics Clarifies Convertible Note Funding and Share Issue Capacity
BCAL Diagnostics has detailed its funding position for FY2027, confirming drawdowns under a $10 million convertible note facility first approved by shareholders in late 2025. The company has issued $3.1 million in notes within the original approval w...
BCAL Diagnostics boosts cancer test rollout, secures U.S. validation and strategic investment
BCAL Diagnostics reported substantial progress in building commercial access to its early cancer detection tests during the June quarter, embedding referral forms into leading GP and specialist software and launching the EarlyDetection.com.au platfor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026